BASEL, Switzerland – October 26, 2020: NBE-Therapeutics, a Swiss-based company developing best-in-class cancer therapies based on its proprietary, highly differentiated Antibody-Drug Conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback